Illumina, Inc.NASDAQ
Advanced Chart
  • Thu, Aug. 18, 9:58 AM
    • Illumina (ILMN +0.7%) has reportedly received a $30B offer from Thermo Fisher Scientific (TMO -0.9%).
    • Illumina, sporting a $25B market cap, is a global leader in molecular diagnostic systems. In Q2 it earned $0.82 a share on revenues of $600M.
    • Large cap ($61B) Thermo is a global leader in clinical diagnostics that generates ~$17B a year in sales.
    | Thu, Aug. 18, 9:58 AM | 21 Comments
  • Tue, Jul. 12, 3:37 PM
    • Illumina (ILMN +6.7%) and Exact Sciences (EXAS +7.1%) head north on rumored interest by Illumina for a takeover. The supposed reason is to acquire tissue mapping expertise/technology as a component of liquid biopsy testing. Exact is collaborating with MAYO Foundation for Medical Education and Research on future DNA tests, including lung (from lung nodules), pancreatic and esophageal cancers. Its only commercially offering is Cologuard, a DNA screening test for colorectal cancer.
    • At least on paper, Sequenom (SQNM +2.1%) appears to be at least as good a target, considering its pooled patent deal with Ilumina and Sequenom's stated desire for strategic partner to develop and commercialize its oncology liquid biopsy test.
    • Exact's market cap is $1.3B while Sequenom's is a mere $112M. As of April 3, Ilumina had $1.34B in quick assets so it will have to issue stock or debt if it wants Exact.
    | Tue, Jul. 12, 3:37 PM | 14 Comments
  • Aug. 4, 2015, 4:19 PM
    • Ilumina (NASDAQ:ILMN) acquires GenoLogics Life Sciences Software, a developer of laboratory information management systems for the life sciences industry, for an undisclosed sum. The deal beefs up Ilumina's portfolio of genetic analysis solutions.
    • The transaction should close by the end of this month.
    | Aug. 4, 2015, 4:19 PM
  • Jul. 16, 2014, 7:04 AM
    • Ilumina (NASDAQ:ILMN) acquires Myraqa, a regulatory and quality consulting form specializing in in vitro diagnostics, especially companion diagnostics. Myraqa's expertise is regulatory strategy and application support, including PMAs, pre-submissions, IDEs, 510(k)s and EU technical files. The acquisition beefs up Ilumina's in-house regulatory capabilities.
    • Myraqa CEO Mya Thomae will report to Ilumina CMO Rick Klausner, M.D.
    | Jul. 16, 2014, 7:04 AM
  • Jul. 23, 2013, 6:31 PM

    In tandem with its Q2 results (I, II), Illumina (ILMN) announces it's acquiring Advanced Liquid Logic, a provider of liquid handling solutions for laboratory/clinic R&D. Illumina says Advanced Liquid has "developed a proprietary digital microfluidics technology based on electrowetting that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols." The tech will be used to improve the DNA sequencing workflow for Illumina's products.

    | Jul. 23, 2013, 6:31 PM
  • Jan. 6, 2013, 8:26 AM

    "Illumina (ILMN) is definitely off the table," says Roche (RHHBY.PK) Chairman Franz Humer, his company walking away from a bid for the 2nd time in a year. "They were not willing to abandon the totally unrealistic price they were asking for ... There are several alternatives to get hold of gene-sequencing technology."

    | Jan. 6, 2013, 8:26 AM
  • Dec. 20, 2012, 7:04 AM

    A report from a newspaper in Switzerland indicates Roche (RHHBY.OB) is close to striking a deal to buy Illumina (ILMN) for $66 a share. The $8.1B acquisition could be announced next month, although some analysts remain skeptical it will fly. ILMN +7.9% premarket to $56.25.

    | Dec. 20, 2012, 7:04 AM
  • Nov. 26, 2012, 12:09 PM
    Ilumina (ILMN -3.6%) slips today on a Baird dowgrade to Neutral. Baird says there are near-term M&A risks, specifically citing ILMN's own bid for Complete Genomics (GNOM +0.2%) while chatter resurfaces about Roche (RHHBY.OB) potentially trying to buy ILMN again after falling to reach a deal earlier this year.
    | Nov. 26, 2012, 12:09 PM
  • Nov. 26, 2012, 8:57 AM

    California Judge Elizabeth Laporte agrees to review an earlier decision to invalidate certain claims of an Illumina (ILMN) patent. The ruling is connected to a case in which the company has accused Complete Genomics (GNOM) - which Illumina is trying to buy - of breaching its IP.

    | Nov. 26, 2012, 8:57 AM
  • Nov. 21, 2012, 11:33 AM
    BGI-Shenzhen has again extended the deadline for its tender offer to acquire Complete Genomics (GNOM +1.6%), a move that comes in response to Illumina's (ILMN +0.8%) recently disclosed competing bid earlier this month that was rejected by the life sciences company. BGI's tender offer now expires on December 14.
    | Nov. 21, 2012, 11:33 AM
  • Nov. 21, 2012, 8:26 AM

    Complete Genomics (GNOM +2.3%) rejects Illumina's (ILMN) $114M bid despite the $3.30/share offer exceeding a $3.15 agreed proposal from China's BGI-Shenzhen. Illumina's bid is also not dependent on funding, nor is it subject to government approval as a foreign investment. Illumina "cannot comprehend" how GNOM "could rationally come to the conclusion" Illumina's offer is not superior. GNOM's shareholders may well agree.

    | Nov. 21, 2012, 8:26 AM
  • Oct. 2, 2012, 9:29 AM

    Illumina (ILMN) +7.1% to $52.44 after the U.K.'s Times newspaper reports (paywall) that Roche (RHHBY.PK) may make another bid for the company at $60 a share. Illumina already rejected a Roche bid of $51 in April.

    | Oct. 2, 2012, 9:29 AM | 1 Comment
  • Apr. 18, 2012, 10:51 AM

    Illumina (ILMN -4.2%) gains a vital victory in its bid to fend off Roche's (RHHBY.PK) advances as shareholders elect all four of Illumina's nominees to its board. Investors also reject Roche's attempts to increase the number of directors and other proposals. Roche said earlier it won't extend its offer.

    | Apr. 18, 2012, 10:51 AM
  • Apr. 18, 2012, 9:36 AM

    Roche (RHHBY.PK) says it will not extend its latest tender offer for Illumina (ILMN): "We do not believe that a price above Roche's offer for Illumina of $51/share would be in the interest of Roche's shareholders." ILMN -7.5% at the open.

    | Apr. 18, 2012, 9:36 AM
  • Apr. 18, 2012, 5:27 AM

    Today is a big day for Illumina (ILMN) in its battle to fend off Roche's (RHHBY.PK) $6.7B bid, with shareholders due to vote on new directors at the company's annual meeting. Roche has made six nominations, which would give it control of the board, although three proxy advisory services have backed Illumina's four candidates.

    | Apr. 18, 2012, 5:27 AM
  • Apr. 12, 2012, 2:54 PM

    Illumina (ILMN -5.6%), which has twice rejected Roche's (RHHBY.PK) takeover bids, drops below the latest $51/share offer price for the first time as investors grow concerned the deal will be abandoned. The offer is “more than adequate to serve as a basis” to start talks and “is full, fair and extremely attractive by every conceivable financial metric,” Roche says today.

    | Apr. 12, 2012, 2:54 PM